Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 7INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × pidilizumab × Clear all
NCT01435369 2016-01-21

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Medivation, Inc.

Phase 2 Completed
103 enrolled
Dermatologic

Melanoma

NCT00890305 2015-07-08

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Medivation, Inc.

Phase 2 Completed
171 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00532259 2014-09-12

CT-011 MAb in DLBCL Patients Following ASCT

CureTech Ltd

Phase 2 Completed
72 enrolled 9 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00966251 2012-10-23

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

CureTech Ltd

Phase 1/2 Terminated
2 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡